A battery of simple tests for profiling abnormalities of vitamin K-dependent coagulation factors encountered in drug-toxicity studies was verified in rats treated with warfarin (3 and 10 mg/kg, p.o). The thrombotest, or hepaplastin-test, is useful as a followup test after routine screening tests for coagulation abnormalities based on PT and APTTThe rat is the species most commonly used to assess the general toxicity of compounds under development for clinical use. We sometimes observe prolongation of the routine screening parameters, prothrombin time (PT) and activated partial thromboplastin time (APTT) in general toxicity studies in rats. One of the causes of this is decreased activity of vitamin K-dependent coagulation factors due to the generation of the inactive des-carboxyl form of coagulation factors, also known as "protein induced by vitamin K absence or antagonists (PIVKA)" [7,12]. Many chemicals are known to cause such abnormalities [8,20].The abnormal vitamin K-dependent factors are detected in rats by measuring coagulation time using the Kurata, Worldwide Safety Sciences, Pfizer Global Research and Development, Nagoya Laboratories, Pfizer Inc., 5-2 Taketoyo, Aichi 470-2393, Japan thrombotest [4, 6, 14, 18], the activity of coagulation factors [9,13], and descarboxyprothrombin (PIVKA-II) [7,8]. The hepaplastin-test is also employed to detect abnormal coagulation factors related to hepatic injury in rats [16,21]. Among them, the thrombotest and hepaplastin-test are the least specific, since these show a prolongation of coagulation time when the activity of either factor II, VII or X has declined, regardless of whether vitamin K abnormality is involved or not. The activity of individual coagulation factors is insufficient to confirm the patho-mechanism of coagulation abnormalities, because it is impossible to detect the inactive form of coagulation factors (e.g., PIVKA-II). PIVKA-II, if measured alone, is also insufficient